Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 109

1.

Achievement of individualized treatment targets in patients with comorbid type-2 diabetes and hypertension: 6 months results of the DIALOGUE registry.

Schmieder RE, Gitt AK, Koch C, Bramlage P, Ouarrak T, Tschöpe D; DIALOGUE study group.

BMC Endocr Disord. 2015 May 2;15(1):23. doi: 10.1186/s12902-015-0020-7.

2.

Gender differences in therapeutic recommendation after diagnostic coronary angiography: insights from the Coronary Angiography and PCI Registry of the German Society of Cardiology.

Heer T, Hochadel M, Schmidt K, Mehilli J, Zahn R, Kuck KH, Hamm C, Böhm M, Ertl G, Andresen D, Massberg S, Senges J, Pilz G, Gitt AK, Zeymer U.

Clin Res Cardiol. 2015 Jan 21. [Epub ahead of print]

PMID:
25875945
3.

A real world comparison of sulfonylurea and insulin vs. incretin-based treatments in patients not controlled on prior metformin monotherapy.

Gitt AK, Bramlage P, Schneider S, Tschöpe D.

Cardiovasc Diabetol. 2015 Feb 3;14:13. doi: 10.1186/s12933-015-0172-9.

4.

Clinical course and outcomes of type-2 diabetic patients after treatment intensification for insufficient glycaemic control - results of the 2 year prospective DiaRegis follow-up.

Bramlage P, Gitt AK, Schneider S, Deeg E, Tschöpe D; DiaRegis Study Group.

BMC Cardiovasc Disord. 2014 Nov 19;14:162. doi: 10.1186/1471-2261-14-162.

5.

[Antithrombotic treatment in patients with stable coronary artery disease. Which drugs and for how long?].

Gitt AK, Zahn R.

Herz. 2014 Nov;39(7):798-802. doi: 10.1007/s00059-014-4171-5. German.

PMID:
25361793
6.

Contemporary real life cardioversion of atrial fibrillation: Results from the multinational RHYTHM-AF study.

Crijns HJ, Weijs B, Fairley AM, Lewalter T, Maggioni AP, Martín A, Ponikowski P, Rosenqvist M, Sanders P, Scanavacca M, Bash LD, Chazelle F, Bernhardt A, Gitt AK, Lip GY, Le Heuzey JY.

Int J Cardiol. 2014 Apr 1;172(3):588-94. doi: 10.1016/j.ijcard.2014.01.099. Epub 2014 Jan 25.

7.

Overtreatment and undertreatment with anticoagulation in relation to cardioversion of atrial fibrillation (the RHYTHM-AF study).

Lip GY, Gitt AK, Le Heuzey JY, Bash LD, Morabito CJ, Bernhardt AA, Sisk CM, Chazelle F, Crijns HJ; RHYTHM-AF Scientific Committee.

Am J Cardiol. 2014 Feb 1;113(3):480-4. doi: 10.1016/j.amjcard.2013.10.036. Epub 2013 Nov 9.

PMID:
24332698
8.

Left circumflex artery-related myocardial infarction: does ST elevation matter? Results from the Euro Heart Survey PCI registry.

Bauer T, Gitt AK, Hochadel M, Möllmann H, Nef H, Weidinger F, Zahn R, Hamm CW, Marco J, Zeymer U.

Int J Cardiol. 2013 Oct 15;168(6):5239-42. doi: 10.1016/j.ijcard.2013.08.024. Epub 2013 Aug 14.

PMID:
23998547
9.

2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology.

Task Force Members, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, Bugiardini R, Crea F, Cuisset T, Di Mario C, Ferreira JR, Gersh BJ, Gitt AK, Hulot JS, Marx N, Opie LH, Pfisterer M, Prescott E, Ruschitzka F, Sabaté M, Senior R, Taggart DP, van der Wall EE, Vrints CJ; ESC Committee for Practice Guidelines, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S; Document Reviewers, Knuuti J, Valgimigli M, Bueno H, Claeys MJ, Donner-Banzhoff N, Erol C, Frank H, Funck-Brentano C, Gaemperli O, Gonzalez-Juanatey JR, Hamilos M, Hasdai D, Husted S, James SK, Kervinen K, Kolh P, Kristensen SD, Lancellotti P, Maggioni AP, Piepoli MF, Pries AR, Romeo F, Rydén L, Simoons ML, Sirnes PA, Steg PG, Timmis A, Wijns W, Windecker S, Yildirir A, Zamorano JL.

Eur Heart J. 2013 Oct;34(38):2949-3003. doi: 10.1093/eurheartj/eht296. Epub 2013 Aug 30. No abstract available. Erratum in: Eur Heart J. 2014 Sep 1;35(33):2260-1.

10.

Prognostic implications of DPP-4 inhibitor vs. sulfonylurea use on top of metformin in a real world setting - results of the 1 year follow-up of the prospective DiaRegis registry.

Gitt AK, Bramlage P, Binz C, Krekler M, Deeg E, Tschöpe D.

Int J Clin Pract. 2013 Oct;67(10):1005-14. doi: 10.1111/ijcp.12179. Epub 2013 Aug 28.

PMID:
23981060
11.

Incidence and clinical impact of stroke complicating percutaneous coronary intervention: results of the Euro heart survey percutaneous coronary interventions registry.

Werner N, Bauer T, Hochadel M, Zahn R, Weidinger F, Marco J, Hamm C, Gitt AK, Zeymer U.

Circ Cardiovasc Interv. 2013 Aug;6(4):362-9. doi: 10.1161/CIRCINTERVENTIONS.112.000170. Epub 2013 Jul 30.

12.

EARLY Treatment with azilsartan compared to ACE-inhibitors in anti-hypertensive therapy--rationale and design of the EARLY hypertension registry.

Gitt AK, Baumgart P, Bramlage P, Mahfoud F, Potthoff SA, Senges J, Schneider S, Buhck H, Schmieder RE; EARLY Registry Group.

BMC Cardiovasc Disord. 2013 Jul 2;13:46. doi: 10.1186/1471-2261-13-46.

13.

Types and outcomes of cardioversion in patients admitted to hospital for atrial fibrillation: results of the German RHYTHM-AF Study.

Gitt AK, Smolka W, Michailov G, Bernhardt A, Pittrow D, Lewalter T.

Clin Res Cardiol. 2013 Oct;102(10):713-23. doi: 10.1007/s00392-013-0586-x. Epub 2013 Jun 30.

PMID:
23812041
14.

The role of co-morbidity in the selection of antidiabetic pharmacotherapy in type-2 diabetes.

Tschöpe D, Hanefeld M, Meier JJ, Gitt AK, Halle M, Bramlage P, Schumm-Draeger PM.

Cardiovasc Diabetol. 2013 Apr 10;12:62. doi: 10.1186/1475-2840-12-62. Review.

15.

Co-morbidity but not dysglycaemia reduces quality of life in patients with type-2 diabetes treated with oral mono- or dual combination therapy--an analysis of the DiaRegis registry.

Wasem J, Bramlage P, Gitt AK, Binz C, Krekler M, Deeg E, Tschöpe D; DiaRegis Study Group.

Cardiovasc Diabetol. 2013 Mar 20;12:47. doi: 10.1186/1475-2840-12-47.

16.

Lipid management in 13,000 high risk cardiovascular patients treated under daily practice conditions: LIMA Registry.

Schaefer JR, Gitt AK, Sonntag F, Weizel A, Jannowitz C, Karmann B, Pittrow D, Bestehorn K.

Vasc Health Risk Manag. 2013;9:71-80. doi: 10.2147/VHRM.S37143. Epub 2013 Feb 21.

17.

Achievement of recommended glucose and blood pressure targets in patients with type 2 diabetes and hypertension in clinical practice - study rationale and protocol of DIALOGUE.

Gitt AK, Schmieder RE, Duetting E, Bramlage P, Schneider S, Tschöpe D; DIALOGUE Study Group.

Cardiovasc Diabetol. 2012 Dec 5;11:148. doi: 10.1186/1475-2840-11-148.

18.

Incidence and predictors of hypoglycaemia in type 2 diabetes - an analysis of the prospective DiaRegis registry.

Tschöpe D, Bramlage P, Binz C, Krekler M, Deeg E, Gitt AK.

BMC Endocr Disord. 2012 Oct 17;12:23. doi: 10.1186/1472-6823-12-23.

19.

Oral antidiabetic treatment in type-2 diabetes in the elderly: balancing the need for glucose control and the risk of hypoglycemia.

Bramlage P, Gitt AK, Binz C, Krekler M, Deeg E, Tschöpe D.

Cardiovasc Diabetol. 2012 Oct 6;11:122. doi: 10.1186/1475-2840-11-122.

20.

RHYTHM-AF: design of an international registry on cardioversion of atrial fibrillation and characteristics of participating centers.

Crijns HJ, Bash LD, Chazelle F, Le Heuzey JY, Lewalter T, Lip GY, Maggioni AP, Martín A, Ponikowski P, Rosenqvist M, Sanders P, Scanavacca M, Bernhardt AA, Unniachan S, Phatak HM, Gitt AK.

BMC Cardiovasc Disord. 2012 Oct 2;12:85. doi: 10.1186/1471-2261-12-85.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk